Trending...
- Cleo Harper Black Friday Offer Sells Out Early
- Men's Health Network Highlights Major 2025 Achievements & Launches New Donation Platform For Greater Impact
- Small Business Owners Need To Go Back To Basics
FAYETTEVILLE, Ark. - AussieJournal -- Lineus Medical, the leader in vascular access innovation, has been awarded a U.S. patent for SafeBreak® Vascular Generation 2, the next evolution of the company's flagship breakaway device. The newly patented design features a single-valve system, replacing the original device's two-valve configuration. The ideas captured in the patent allow the device to have a significantly smaller profile while maintaining the device's core function of protecting IV lines from damaging external forces by separating. The patent also includes the ability to add a light and/or sound notification for nurses when the device separates. The current version of SafeBreak relies on IV pump alarm to alert nurses of a separation. Having an alarm on SafeBreak will help open up the home healthcare and gravity line IV market for the company.
SafeBreak Vascular is the only breakaway device for IV lines clinically proven to reduce multiple IV complications.¹ When a damaging force is placed on the line, SafeBreak intentionally separates to remove the force and protect the patient's IV. When separation occurs, valves on both ends of the device close to prevent medication leakage from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money.1
More on Aussie Journal
"Lineus Medical continues to innovate and be the thought leader both clinically and scientifically in the breakaway device market.", said Vance Clement, CEO of Lineus Medical. "SafeBreak Gen 2 will move us closer to accomplishing our mission of removing the pains associated with IV lines for patients, nurses, and hospitals."
"The SafeBreak Gen 2 design reflects our ongoing commitment to the continuous improvement of SafeBreak," said Will Armstrong, COO of Lineus Medical. "This patent showcases how our engineering team is advancing breakaway device technology with smarter, simpler design solutions that improve patient care while further strengthening the company's intellectual property portfolio."
About Lineus Medical
Lineus Medical is the developer of SafeBreak® Vascular, a breakaway technology proven to reduce IV restarts and IV complications.¹ More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.
References:
1. Data on file.
SafeBreak Vascular is the only breakaway device for IV lines clinically proven to reduce multiple IV complications.¹ When a damaging force is placed on the line, SafeBreak intentionally separates to remove the force and protect the patient's IV. When separation occurs, valves on both ends of the device close to prevent medication leakage from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money.1
More on Aussie Journal
- Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
- Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
- Canterbury Hotel Group Announces the Opening of the TownePlace Suites by Marriott Portland Airport
- Heritage at South Brunswick's Resort-Style Amenities for Any Age and Every Lifestyle
- T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
"Lineus Medical continues to innovate and be the thought leader both clinically and scientifically in the breakaway device market.", said Vance Clement, CEO of Lineus Medical. "SafeBreak Gen 2 will move us closer to accomplishing our mission of removing the pains associated with IV lines for patients, nurses, and hospitals."
"The SafeBreak Gen 2 design reflects our ongoing commitment to the continuous improvement of SafeBreak," said Will Armstrong, COO of Lineus Medical. "This patent showcases how our engineering team is advancing breakaway device technology with smarter, simpler design solutions that improve patient care while further strengthening the company's intellectual property portfolio."
About Lineus Medical
Lineus Medical is the developer of SafeBreak® Vascular, a breakaway technology proven to reduce IV restarts and IV complications.¹ More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.
References:
1. Data on file.
Source: Lineus Medical
Filed Under: Technology
0 Comments
Latest on Aussie Journal
- Super on Payday: Fundamental Changes for Employers
- NatureHelm Co-Founders Attended Asia-Pacific Agri-Food Innovation Summit in Singapore
- Take Control of Your Color Matching with Boston Industrial Solutions' Newly Expanded Natron® UVPX Series Ink Colors
- "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
- Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
- Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
- LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
- Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model
- Qtex Cierra Ronda de $7 Millones para Estandarizar la Banca Transfronteriza en los Mercados Emergentes de Latinoamérica
- America's Most Festive Garages Wanted for Garage.com's 2025 Holiday Contest
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
- BEC Technologies Expands MX-220 5G Industrial Router Series for Edge Connectivity
- "Latino Leaders Speak: Personal Stories of Struggle and Triumph, Volume II" Documents the Truth About Latino Excellence and Impact on American Society
- Broadway Smile Boutique Unveils Modern Website for Enhanced Patient Experience

